PMID- 28741673
OWN - NLM
STAT- MEDLINE
DCOM- 20180608
LR  - 20220316
IS  - 1600-0404 (Electronic)
IS  - 0001-6314 (Linking)
VI  - 137
IP  - 1
DP  - 2018 Jan
TI  - Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy.
PG  - 29-32
LID - 10.1111/ane.12803 [doi]
AB  - OBJECTIVE: The aim of the study was to assess the clinical response to 
      eslicarbazepine acetate (ESL) as add-on therapy in adult patients with 
      partial-onset epilepsy by means of the time-to-baseline seizure count method. 
      METHODS: We retrospectively identified consecutive patients with partial-onset 
      seizures, with or without secondary generalization, prescribed to ESL add-on 
      therapy. The primary endpoint was the time-to-baseline monthly seizure count. 
      Subgroup analysis was performed according to carbamazepine (CBZ)/oxcarbazepine 
      (OXC) status (prior vs never use). Secondary outcomes were the rate of 
      treatment-related adverse events (AEs) and the AEs affecting >/=5% of patients. 
      RESULTS: One-hundred and eighteen patients were included. The median 
      time-to-baseline monthly seizure count was 46 (35-101) days in the overall study 
      cohort. The number of concomitant anti-epileptic drugs (AEDs) was associated with 
      the time-to-endpoint (adjusted hazard ratio [(adj) HR]=2.22, 95% CI 1.18-4.14, 
      P=.013 for two AEDs vs one; (adj) HR=3.65, 95% CI 1.66-8.06, P=.001 for three or 
      more AEDs vs one). Groupwise, the median times-to-baseline seizure count were 47 
      (35-97) and 43 (34-103) in patients with prior and never exposure to CBZ/OXC, 
      respectively (P for log-rank test=.807). Adverse events occurred in 53.4% (63 of 
      118) of patients; the most frequently reported were dizziness (13.6%), somnolence 
      (11.9%), nausea (6.8%), and fatigue (5.1%). CONCLUSIONS: Add-on ESL improved 
      seizure control and was overall well-tolerated in adult patients with 
      partial-onset epilepsy.
CI  - (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Lattanzi, S
AU  - Lattanzi S
AUID- ORCID: 0000-0001-8748-0083
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Cagnetti, C
AU  - Cagnetti C
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Foschi, N
AU  - Foschi N
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Lorusso, A
AU  - Lorusso A
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Provinciali, L
AU  - Provinciali L
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
FAU - Silvestrini, M
AU  - Silvestrini M
AD  - Neurological Clinic, Department of Experimental and Clinical Medicine, Marche 
      Polytechnic University, Ancona, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170725
PL  - Denmark
TA  - Acta Neurol Scand
JT  - Acta neurologica Scandinavica
JID - 0370336
RN  - 0 (Anticonvulsants)
RN  - 0 (Dibenzazepines)
RN  - 33CM23913M (Carbamazepine)
RN  - BEA68ZVB2K (eslicarbazepine acetate)
RN  - VZI5B1W380 (Oxcarbazepine)
SB  - IM
MH  - Adult
MH  - Anticonvulsants/*administration & dosage/adverse effects
MH  - Carbamazepine/administration & dosage/analogs & derivatives
MH  - Dibenzazepines/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination/methods
MH  - Epilepsies, Partial/*drug therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxcarbazepine
MH  - Retrospective Studies
MH  - Seizures/drug therapy
MH  - Young Adult
OTO - NOTNLM
OT  - anti-epileptic drugs
OT  - epilepsy
OT  - eslicarbazepine acetate
EDAT- 2017/07/26 06:00
MHDA- 2018/06/09 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/07/03 00:00 [accepted]
PHST- 2017/07/26 06:00 [pubmed]
PHST- 2018/06/09 06:00 [medline]
PHST- 2017/07/26 06:00 [entrez]
AID - 10.1111/ane.12803 [doi]
PST - ppublish
SO  - Acta Neurol Scand. 2018 Jan;137(1):29-32. doi: 10.1111/ane.12803. Epub 2017 Jul 
      25.